AVEO Pharmaceuticals, Inc. (AVEO) Sees Strong Trading Volume
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) saw unusually-high trading volume on Wednesday . Approximately 7,870,129 shares were traded during mid-day trading, an increase of 42% from the previous session’s volume of 5,547,270 shares.The stock last traded at $3.94 and had previously closed at $3.73.
AVEO has been the subject of a number of research analyst reports. Zacks Investment Research raised AVEO Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.75 price target for the company in a research note on Monday, July 24th. Piper Jaffray Companies raised their price target on AVEO Pharmaceuticals from $3.80 to $4.50 and gave the stock an “overweight” rating in a research note on Monday, August 28th. FBR & Co reaffirmed an “outperform” rating and issued a $3.00 price target on shares of AVEO Pharmaceuticals in a research note on Thursday, July 13th. BidaskClub raised AVEO Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, August 16th. Finally, ValuEngine raised AVEO Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 24th. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. AVEO Pharmaceuticals currently has an average rating of “Buy” and an average target price of $3.42.
The company has a 50 day moving average price of $3.56 and a 200 day moving average price of $1.89. The firm’s market capitalization is $466.13 million.
A number of institutional investors have recently made changes to their positions in the business. Cannell Peter B & Co. Inc. grew its position in AVEO Pharmaceuticals by 22.9% in the 2nd quarter. Cannell Peter B & Co. Inc. now owns 109,875 shares of the biopharmaceutical company’s stock valued at $244,000 after acquiring an additional 20,500 shares during the last quarter. Fore Research & Management LP bought a new position in AVEO Pharmaceuticals in the 2nd quarter valued at $111,000. Clear Harbor Asset Management LLC bought a new position in AVEO Pharmaceuticals in the 2nd quarter valued at $289,000. Paloma Partners Management Co bought a new position in AVEO Pharmaceuticals in the 1st quarter valued at $184,000. Finally, UBS Oconnor LLC bought a new position in AVEO Pharmaceuticals in the 1st quarter valued at $291,000. 53.76% of the stock is currently owned by institutional investors.
About AVEO Pharmaceuticals
AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.
Receive News & Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.